) The overall goal of the Tobacco Related Malignancies Program is to decrease the incidence, morbidity, and mortality of tobacco induced cancers of the aerodigestive tract. The Program is comprised of 28 investigators with interests in various aspects of carcinogenesis, genetics, cell signaling/biology, clinical trials and primary prevention/screening/early detection. The Program includes both basic and clinical scientists with complementary interests. Clinical specialities include Medical Oncology, Radiation Oncology, Pathology, Pulmonary Medicine, General Internal Medicine, Psychiatry, Immunology, Dentistry, Head and Neck and Thoracic Surgery. Interactions between members are promoted by a twice-monthly research seminar, day-long or half-day symposia and individual outside speakers. A weekly Pulmonary/Thoracic/Oncology multidisciplinary conference and a weekly Head and Neck Tumor conference promote the enrollment of patients onto therapeutic trials. A Career Development Program has been successful in supporting young faculty members who have gone on to careers in research related to tobacco induced cancer. A Developmental Program has supported pilot projects, several of which have subsequently resulted in independent funding. Several novel therapeutic strategies based on basic and preclinical work at our institution are now being translated to human trials, including one supported by an NCI RAID. In addition to individual research grants, interactions between program members have resulted in several multi-investigator proposals, including a Specialized Program of Research Excellence in Lung Cancer, Genetic Epidemiology of Lung Cancer Consortium, Lung Cancer Biomarkers and Chemoprevention Consortium, a Biomarkers Development Component of the Early Detection Research Network and an NCI/NIDA Transdisciplinary Tobacco Use Research Center; all but the last of these were fully funded. Several parts of the latter were funded as were several other tobacco projects described in the Clinical and Community Prevention and Control Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-14
Application #
6488584
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications